HRP20050743A2 - 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis - Google Patents

3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis

Info

Publication number
HRP20050743A2
HRP20050743A2 HR20050743A HRP20050743A HRP20050743A2 HR P20050743 A2 HRP20050743 A2 HR P20050743A2 HR 20050743 A HR20050743 A HR 20050743A HR P20050743 A HRP20050743 A HR P20050743A HR P20050743 A2 HRP20050743 A2 HR P20050743A2
Authority
HR
Croatia
Prior art keywords
acetic acid
methoxy
cyclohexylmethoxy
oxazol
arteriosclerosis
Prior art date
Application number
HR20050743A
Other languages
English (en)
Croatian (hr)
Inventor
Stapper Christian
Gretzke Dirk
Glombik Heiner
Falk Eugen
Goerlitzer Jochen
Keil Stefanie
Schaefer Hans-Ludwig
Wendler Wolfgang
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20050743A2 publication Critical patent/HRP20050743A2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
HR20050743A 2003-02-27 2005-08-26 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis HRP20050743A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001579 WO2004076427A1 (fr) 2003-02-27 2004-02-19 Derives d'acide acetique 3-(2-phenyl-oxazol-4- ylmethoxy)-cyclohexylmethoxy et composes apparentes comme modulateurs ppar pour traiter le diabete de type 2 et l'atherosclerose

Publications (1)

Publication Number Publication Date
HRP20050743A2 true HRP20050743A2 (en) 2006-08-31

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20050744A HRP20050744A2 (en) 2003-02-27 2005-08-26 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis
HR20050743A HRP20050743A2 (en) 2003-02-27 2005-08-26 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
HR20050742A HRP20050742A2 (en) 2003-02-27 2005-08-26 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20050744A HRP20050744A2 (en) 2003-02-27 2005-08-26 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20050742A HRP20050742A2 (en) 2003-02-27 2005-08-26 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Country Status (34)

Country Link
US (5) US7259177B2 (fr)
EP (3) EP1599455B1 (fr)
JP (3) JP2006519194A (fr)
KR (3) KR20050105492A (fr)
CN (3) CN100439345C (fr)
AR (3) AR043433A1 (fr)
AT (3) ATE430738T1 (fr)
AU (3) AU2004215672B2 (fr)
BR (3) BRPI0407758A (fr)
CA (3) CA2516620A1 (fr)
CL (2) CL2004000392A1 (fr)
CO (2) CO5690580A2 (fr)
DE (4) DE10308355A1 (fr)
DK (3) DK1599453T3 (fr)
EC (2) ECSP055985A (fr)
ES (3) ES2329366T3 (fr)
HR (3) HRP20050744A2 (fr)
IL (2) IL170314A (fr)
MA (3) MA27736A1 (fr)
MX (3) MXPA05008988A (fr)
NO (3) NO20054398L (fr)
OA (2) OA13035A (fr)
PA (1) PA8596801A1 (fr)
PE (3) PE20050292A1 (fr)
PL (3) PL378130A1 (fr)
PT (3) PT1599453E (fr)
RS (1) RS20050594A (fr)
RU (3) RU2005129992A (fr)
SA (1) SA04250153A (fr)
TN (2) TNSN05204A1 (fr)
TW (3) TW200508210A (fr)
UY (2) UY28209A1 (fr)
WO (3) WO2004076428A1 (fr)
ZA (2) ZA200505765B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
WO2007039177A2 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
KR101398715B1 (ko) 2006-08-10 2014-05-27 가부시키가이샤 미모잭스 아카시아속 나무 껍질 유래물을 함유하는 혈당 강하 조성물
EP2181087B1 (fr) 2007-08-16 2015-10-14 Solvay Sa Procédé de préparation d'esters d'acides 3-oxo-alcanoïques substitués par fluoro en position 4
PT2246343T (pt) * 2008-02-29 2016-08-05 Nissan Chemical Ind Ltd Processo de produção de composto de tiofeno e seu intermediário
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116414014A (zh) 2017-12-13 2023-07-11 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
KR20010021936A (ko) 1997-07-16 2001-03-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
EP1108713A4 (fr) * 1998-08-27 2006-04-05 Ono Pharmaceutical Co Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000063208A1 (fr) 1999-04-16 2000-10-26 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
DE60035682T2 (de) 1999-04-28 2008-04-30 Sanofi-Aventis Deutschland Gmbh Di-aryl-säurederivate als ppar rezeptor liganden
DE60027420T2 (de) * 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
US6284766B1 (en) 1999-04-30 2001-09-04 Neurogen Corporation 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
WO2001004146A2 (fr) 1999-07-09 2001-01-18 Cohesion Technologies, Inc. Polypeptides d'ecarine, polynucleotides codant pour l'ecarine, et procedes d'utilisation associes
EP1204654B1 (fr) 1999-07-29 2003-07-23 Eli Lilly And Company Benzofurylpiperazines: agonistes du recepteur 5-ht2c de la serotonine
CA2383781A1 (fr) * 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Derives de sulfonylcarboxamide, leur procede de production et leur utilisation comme medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
WO2001040171A1 (fr) 1999-12-03 2001-06-07 Astrazeneca Ab Forme cristalline d'acide (s)-2-ethoxy-3-[4-(2-{methanesulfonyloxyphenyl}ezhoxy)phenyl] propanoique
ATE419036T1 (de) 2000-03-31 2009-01-15 Prosidion Ltd Verbesserung der aktivität der inselzellen bei diabetes mellitus und dessen prävention
EP1277745A4 (fr) 2000-04-25 2004-09-15 Kyorin Seiyaku Kk Nouveau cristal stable de derive thiazolidinedione et son procede de production
DK1277736T3 (da) 2000-04-28 2007-10-01 Asahi Kasei Pharma Corp Hidtil ukendte bicykliske forbindelser
JP2004507456A (ja) 2000-05-11 2004-03-11 ブリストル−マイヤーズ スクイブ カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
CA2410597A1 (fr) 2000-05-30 2001-12-06 Merck & Co., Inc. Agonistes du recepteur de la melanocortine
DK1294682T3 (da) 2000-06-09 2004-08-02 Aventis Pharma Gmbh Acylphenylurinstofderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (fr) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Procédé pour l'identification de composés inhibant la protéolyse de IkB par l'ubiquitine
ES2288982T3 (es) 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
KR20030027054A (ko) * 2000-08-23 2003-04-03 일라이 릴리 앤드 캄파니 옥사졸릴-아릴프로피온산 유도체 및 ppar효능제로서의 그의 용도
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
IL156550A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
ATE370130T1 (de) * 2000-12-25 2007-09-15 Ono Pharmaceutical Co Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
BR0207285A (pt) * 2001-02-15 2004-02-10 Pfizer Producs Inc Agonistas de ppar
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
ES2275887T3 (es) * 2001-06-07 2007-06-16 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisoma (ppar).
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (fr) 2001-07-03 2003-01-16 Biovitrum Ab Composes nouveaux
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
DK1425014T3 (da) 2001-08-31 2007-04-10 Sanofi Aventis Deutschland Diarylcycloalkylderivater, fremgangsmåde til deres fremstilling og deres anvendelse som PPAR-aktivatorer
ATE433440T1 (de) 2002-02-05 2009-06-15 Lilly Co Eli Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (fr) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Derives heterocycliques substitues utilises en tant qu'agents contre le diabete et contre l'obesite, et methode associee
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
ES2329366T3 (es) 2009-11-25
US20080167354A1 (en) 2008-07-10
DK1599455T3 (da) 2009-11-09
ES2287700T3 (es) 2007-12-16
DE10308355A1 (de) 2004-12-23
BRPI0407758A (pt) 2006-02-14
KR20050105492A (ko) 2005-11-04
PT1599453E (pt) 2009-07-14
US7335671B2 (en) 2008-02-26
CN1756748A (zh) 2006-04-05
JP2006519194A (ja) 2006-08-24
DK1599453T3 (da) 2009-08-24
AU2004215673A1 (en) 2004-09-10
CN1753879A (zh) 2006-03-29
TNSN05204A1 (en) 2007-06-11
MXPA05008988A (es) 2005-10-18
US20080015238A1 (en) 2008-01-17
ZA200505765B (en) 2006-05-31
NO20054398L (no) 2005-11-02
CO5690578A2 (es) 2006-10-31
US20040209920A1 (en) 2004-10-21
CN100439347C (zh) 2008-12-03
HRP20050744A2 (en) 2006-09-30
RU2005129995A (ru) 2006-01-27
US7872034B2 (en) 2011-01-18
MA27736A1 (fr) 2006-02-01
CA2517386A1 (fr) 2004-09-10
WO2004076427A1 (fr) 2004-09-10
BRPI0407814A (pt) 2006-02-14
OA13035A (en) 2006-11-10
US20050101637A1 (en) 2005-05-12
WO2004076428A1 (fr) 2004-09-10
ATE430738T1 (de) 2009-05-15
TW200500349A (en) 2005-01-01
US7365084B2 (en) 2008-04-29
JP2006519199A (ja) 2006-08-24
ATE365159T1 (de) 2007-07-15
AR043432A1 (es) 2005-07-27
RS20050594A (en) 2007-12-31
DE502004004139D1 (de) 2007-08-02
SA04250153A (ar) 2005-12-03
PE20050293A1 (es) 2005-05-24
ECSP055986A (es) 2006-01-16
PE20040959A1 (es) 2005-01-17
PL378437A1 (pl) 2006-04-03
CL2004000391A1 (es) 2005-01-07
DK1599452T3 (da) 2007-10-01
EP1599455B1 (fr) 2009-07-01
AU2004215677B2 (en) 2010-01-07
AU2004215677A1 (en) 2004-09-10
AU2004215672A1 (en) 2004-09-10
CN1753881A (zh) 2006-03-29
KR20050106462A (ko) 2005-11-09
EP1599453A1 (fr) 2005-11-30
UY28210A1 (es) 2004-09-30
EP1599453B1 (fr) 2009-05-06
US20050215596A1 (en) 2005-09-29
CA2516620A1 (fr) 2004-09-10
NO20054396D0 (no) 2005-09-22
PL377735A1 (pl) 2006-02-20
NO20054396L (no) 2005-11-11
TNSN05206A1 (en) 2007-06-11
US7259177B2 (en) 2007-08-21
ATE435217T1 (de) 2009-07-15
NO20054408D0 (no) 2005-09-22
AU2004215672B2 (en) 2010-01-07
WO2004076426A1 (fr) 2004-09-10
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
TW200508210A (en) 2005-03-01
CL2004000392A1 (es) 2005-04-22
DE502004009690D1 (de) 2009-08-13
BRPI0407907A (pt) 2006-02-14
CA2517381A1 (fr) 2004-09-10
DE502004009453D1 (de) 2009-06-18
PT1599455E (pt) 2009-09-29
ECSP055985A (es) 2006-01-16
HRP20050742A2 (en) 2006-09-30
JP2006519193A (ja) 2006-08-24
PT1599452E (pt) 2007-09-12
CN100398526C (zh) 2008-07-02
MXPA05008951A (es) 2005-11-04
EP1599452A1 (fr) 2005-11-30
UY28209A1 (es) 2004-09-30
PL378130A1 (pl) 2006-03-06
EP1599455A1 (fr) 2005-11-30
MXPA05008995A (es) 2005-10-18
EP1599452B1 (fr) 2007-06-20
KR20050106461A (ko) 2005-11-09
MA27742A1 (fr) 2006-02-01
AR043427A1 (es) 2005-07-27
CN100439345C (zh) 2008-12-03
CO5690580A2 (es) 2006-10-31
OA13034A (en) 2006-11-10
MA27737A1 (fr) 2006-02-01
IL170314A (en) 2010-11-30
AR043433A1 (es) 2005-07-27
AU2004215673B2 (en) 2009-10-01
ZA200505768B (en) 2005-11-23
RU2005129992A (ru) 2006-02-10
TW200510352A (en) 2005-03-16
RU2005130002A (ru) 2006-01-27
ES2326418T3 (es) 2009-10-09
NO20054398D0 (no) 2005-09-22
IL170316A (en) 2010-11-30
PE20050292A1 (es) 2005-05-24

Similar Documents

Publication Publication Date Title
HRP20050743A2 (en) 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
HRP20050531B1 (hr) Novi aromatski derivati fluorglikozida, lijek koji sadrži te spojeve i njihova upotreba
HRP20050532A2 (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
EP1784388B8 (fr) Derivés d'acide biphényloxyacétique pour le traitement de la maladie respiratoire
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
DE602004017174D1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
SE0301010D0 (sv) Novel compounds
MEP60708A (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
HRP20050308A2 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
DE502005008971D1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on-verbindungen zur behandlung von fettsucht
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
EA200501399A1 (ru) Производные бензопирана, которые могут использоваться при лечении воспалительных заболеваний
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
MXPA05008993A (es) Derivados de diarilcicloalquilo, metodo para su produccion y su uso como medicamentos.
HRP20050715A2 (en) Substituted 3-(benzoylureido)-thiophene derivatives, method for the production and use thereof
HRP20050737A2 (en) Arylcycloalkyl derivatives with branched side chains as ppar receptor modulators, method for their production and their use as medicaments
HRP20050739A2 (en) Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament
NO20054418L (no) Substituert benzoylureidopyridylpiperidin- og -pyrrolidinkarboksylsyrederivater, deres fremstilling og anvendelse
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
EA201001688A1 (ru) Производные арилпиразинона стимуляторы секреции инсулина, способы их получения и их применение для лечения диабета

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051229

Year of fee payment: 3

A1OB Publication of a patent application
OBST Application withdrawn